GeoVax Labs, Inc. is a clinical-stage biotechnology company headquartered in Smyrna, Georgia, dedicated to the development of pioneering vaccines and immunotherapies for infectious diseases and cancers. Utilizing a proprietary modified vaccinia Ankara virus-like particle platform, the company is advancing its innovative pipeline of therapeutic candidates through multiple clinical trial stages. GeoVax's focus on addressing critical unmet medical needs and its commitment to cutting-edge vaccine technology establish it as a key player in the rapidly evolving fields of immunotherapy and infectious disease prevention, positioning the company for substantial contributions to public health and therapeutic advancements.